The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
ALSFRS-R score and its ratio: A useful predictor for ALS-progression
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder. To determine predictors of survival, we studied different parameters in our ALS Database including 479 patients. The effects of individual prognostic factors of survival were studied using Kaplan-Meier life table. The prognostic value of each factor of interest was expressed in terms of a hazard ratio. Survival from symptom-onset ranged from 4 months up to 11.9 years. Gender had no effect on survival in our cohort. However, age, site of onset, forced vital capacity, symptom duration and ALSFRS-R score at the first visit were independent prognostic factors in our population (log-rank p<0.01). The ratio of ALSFRS-R score between first symptom and first examination, during whole disease or within 100 days, correlates with survival time. We conclude that the ratio of ALSFRS-R score within 100 days is a useful parameter for clinical trials and daily clinical work in a tertiary ALS-clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ALSFRS-R is a widely used and validated measure to evaluate functional status in ALS (20).”
From Chronic Traumatic Encephalopathy Within an Amyotrophic Lateral Sclerosis Brain Bank Cohort (2018) · cites this paper as [20]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433
Cedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00210-5 · Cited by 3,307
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
Bensimon, G., Lacomblez, L., & Meininger, V. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300901 · Cited by 2,239
Brooks, B. R. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90191-0 · Cited by 2,171
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L., Bensimon, G., Meininger, V., Leigh, P. N., & Guillet, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91680-3 · Cited by 1,303
Haverkamp, L. J., Appel, V., & Appel, S. H. (1995) · Brain · doi:10.1093/brain/118.3.707 · Cited by 697
Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS
文治, 木., Fujimura, C., Ishida, S., Nakajima, H., Furutama, D., Uehara, H., Shinoda, K., Sugino, M., & Hanafusa, T. (2006) · Neurology · doi:10.1212/01.wnl.0000194316.91908.8a · Cited by 568
Prognosis in amyotrophic lateral sclerosis: A population-based study
del Aguila, M. A., Longstreth, W. T., McGuire, V., Koepsell, T. D., & van Belle, G. (2003) · Neurology · doi:10.1212/01.wnl.0000049472.47709.3b · Cited by 469
Cited by
Sorted by citations
Prognostic factors in ALS: A critical review
Chiò, A., Logroscino, G., Hardiman, O., Swingler, R., Mitchell, D., Beghi, E., Traynor, B. G., & On Behalf of the Eurals Consortium (2009) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482960802566824 · Cited by 1,172
Regulatory T‐lymphocytes mediate amyotrophic lateral sclerosis progression and survival
Henkel-Tigges, J., Beers, D. R., Wen, S., Rivera, A. L., Toennis, K. M., Appel, J. E., Zhao, W., Moore, D. H., Powell, S. Z.-E., & Appel, S. H. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201544 · Cited by 355
Glass, J. D., Boulis, N. M., Johe, K. K., Rutkove, S. B., Federici, T., Polak, M. A., Kelly, C. M., & Feldman, E. L. (2012) · Stem Cells · doi:10.1002/stem.1079 · Cited by 298
Hypermetabolism in ALS is associated with greater functional decline and shorter survival
Steyn, F. J., Ioannides, Z. A., van Eijk, R. P. A., Heggie, S., Thorpe, K., Ceslis, A., Heshmat, S., Henders, A. K., Wray, N. R., van den Berg, L. H., et al. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317887 · Cited by 245
Mora, J. S., Genge, A. L., Chiò, A., Estol, C. J., Chaverri, D., Hernández, M., Marín, S., Cadavid, J. M., Rodriguez, G. E., Povedano, M., et al. (2019) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2019.1632346 · Cited by 233
Metadata
- Authors
- Kollewe, K., Mauss, U., Krampfl, K., Petri, S., Dengler, R., & Mohammadi, B.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Mohammadi, Bahram
- Venue
- Journal of the Neurological Sciences
- Publisher
- Elsevier BV
- Published
- 2008-12
- Volume
- 275
- Issue
- 1-2
- Pages
- 69-73
- ISSN
- 0022-510X (ISSN-L)
- OpenAlex
- W2026980091
- Cited by
- 253
- References
- 38
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 18 · 2023: 15 · 2022: 21 · 2021: 13 · 2020: 15 · 2019: 18 · 2018: 26 · 2017: 15 · 2016: 19 · 2015: 23 · 2014: 15 · 2013: 7 · 2012: 11
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of the Neurological Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- amyotrophic lateral sclerosis, ALSFRS-R, disease progression, survival prediction, prognostic factors, symptom onset, age, forced vital capacity, symptom duration, hazard ratio
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Amyotrophic Lateral Sclerosis, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Severity of Illness Index, Cohort Studies, Age of Onset, Disease Progression, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
